# OnCo record paper-ck-301-101-jitc-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-ck-301-101-jitc-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-ck-301-101-jitc-2023" ;
  schema:name "Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma"@en ;
  schema:description "The primary report of the metastatic cohort of CK-301-101: cosibelimab shrank tumours in 37 of 78 patients, most responses were still going at the cut-off, and severe immune side effects were uncommon."@en ;
  schema:url <https://onco.cc/key-papers/paper-ck-301-101-jitc-2023/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1136/jitc-2023-007637>, <https://pubmed.ncbi.nlm.nih.gov/37848259/>, <https://clinicaltrials.gov/study/NCT03212404> ;
  schema:sameAs <https://doi.org/10.1136/jitc-2023-007637> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Clingan P, Ladwa R, Brungs D, et al." ;
  onco:cancers <https://onco.cc/cancers/cutaneous-scc/>, <https://onco.cc/cancers/advanced-cutaneous-scc/> ;
  onco:targets <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/cosibelimab/> ;
  onco:companies <https://onco.cc/companies/checkpoint-therapeutics/> ;
  onco:trials <https://onco.cc/trials/ck-301-101/> ;
  onco:journals <https://onco.cc/journals/jitc/> .